FDA Pediatric Request Procedure Should Be Shortened - R.W. Johnson
This article was originally published in The Tan Sheet
Executive Summary
Inclusion in FDA's "priority list" of pediatric drugs should constitute a pediatric study request for a drug, R.W. Johnson Pharmaceutical Research Institute Pediatric Drug Development Global Head Stephen Spielberg, MD/PhD, suggested at an FDA Modernization Act oversight hearing by the House Commerce Committee Oct. 7.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning